11
May

2ND ANNUAL CDx & PERSONALIZED MEDICINE SUMMIT

Categories:

2ND ANNUAL CDx & PERSONALIZED MEDICINE SUMMIT

Personalized medicine will change the way medicine is practiced. The new therapies will benefit both patients and physicians in many ways. Patients will experience fewer side effects and physicians will be armed with more precise tools and medicine. Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This premier B2B summit will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in the CDx.

The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices within the companion diagnostics (CDx) industry. More importantly, partnership opportunities and commercializing CDx tests with pharmaceutical and biotech companies will be explored.

KEY TOPICS

WHY YOU SHOULD BE THERE ?

Novel Diagnostic Technologies
Strategic Partnerships for CDx – Challenges and Opportunities
Partnering strategies to achieve successful commercialization of CDx
Future key areas for the Development of Personalized Medicine
Partnering to Deliver Personalized Medicine
Finding the appropriate business models for CDx companies
Development of new Business Models for the Healthcare Industry
The role of complementary diagnostics in targeted therapy selection
Regulatory Update on Companion Diagnostics
Emerging investment trends and opportunities
Regulatory and Commercial Considerations

1. Meet with experts and influencers in your industry face to face.

2. Learn about the latest technologies and most pressing topics specific to your business.

3. Discuss about new opportunities for your products and services with key decision makers.

4. Get new tips, tactics and implement the latest innovations.

5. Get an overview on innovative emerging technologies and business partnership opportunities.

6. Interact and connect with leading companies and their representatives.

MEDIA PARTNERS

REQUEST FORM

YOUR FULL NAME *

COMPANY NAME *

TELEPHONE

CORPORATE EMAIL *

HOW CAN WE HELP YOU?

PICK THE EVENT YOU'RE INTERESTED IN

MESSAGE

Click here to indicate that you have read and agree to our privacy policy.

27
Nov

2nd Annual Cancer Immunotherapy Summit

Categories:

2ND ANNUAL CANCER IMMUNOTHERAPY SUMMIT

In this summit, the most successful and promising new cancer treatment strategies will be explored. This summit is one of the most important opportunities, where you will explore the best practices in cancer immunotherapy. It is particularly important for the fields key opinion leaders, most exciting newcomers and others to come together to discuss and learn about the up-to-the-minute trends.

The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities. This premier B2B summit is one of the few opportunities, where you will meet face to face with leading industry professionals and decision makers and discuss your business potential and opportunities. It will also enable the participants to learn about the most advanced techniques and tools through which they can assess their portfolios and development potential.

KEY TOPICS

EU and US Regulatory aspects

Management of side effects

What’s new in specific cancer types – News in specific cancer types

The true potential of the next generation immune checkpoint pathways

Resistance to therapy

Patient selection and predictive biomarkers

Advancements in T-cell engineering

Commercialization of Viable T-cell therapies

Revolutionary cancer treatment with personalised cancer vaccines

Combining immune checkpoint inhibitors with chemotherapy or radiotherapy and beyond

Technological developments

Preclinical and clinical progress in Cancer Immunotherapy

Advanced methods, technological developments and strategies in Cancer Immunotherapy

Imaging and nuclear medicine and design of immuno-oncology trials

Progressive genetic engineering techniques

WHY YOU SHOULD BE HERE?

Network with business development and licensing professionals as well as professionals in your sector

Implement the latest innovations

Learn about the latest technologies and most pressing topics specific to your business

Get an overview on innovative emerging technologies and promote business partnerships within the sector

Interact and connect with leading professionals

Discuss about new opportunities for your products and services with key decision makers

FEATURED SPEAKERS

Ivan Diaz-Padilla, MD, PhD

Senior Medical Director Oncology Global Development

Novartis

Louis Boon

Chief Scientific Officer

Bioceros

Dr. John Maher

Clinical Senior Lecturer/Honorary Consultant in Immunology

Kings College London

Dr. Marek Štastný, PhD.

Senior Scientific Advisor Oncology/Immuno-oncology

Bristol-Myers Squibb

Stefanos Theoharis

SVP Corporate Development and Partnering

Cell Medica

Larissa S. Carnevalli, PhD

Associate Principal Scientist Oncology Disease Models and Mechanisms Group

AstraZeneca

Madalin Sevestrian

Scientist

PAREXEL

Ronald Kurt Kuoch

Biomarker & Diagnostics Biopharma Global Early Development

Merck

FEATURED COMPANIES

MEDIA PARTNERS

REQUEST FORM

YOUR FULL NAME *

COMPANY NAME *

TELEPHONE

CORPORATE EMAIL *

HOW CAN WE HELP YOU?

PICK THE EVENT YOU'RE INTERESTED IN

MESSAGE

Click here to indicate that you have read and agree to our privacy policy.

28
Feb

INTERNATIONAL BIOSIMILARS SUMMIT

Categories:

INTERNATIONAL BIOSIMILARS SUMMIT

The biosimilars industry landscape is rapidly evolving and creating significant revenue opportunities for companies that can successfully develop and market them. According to the GBI research global biosimilars market value could hit $55 billion by 2020 from its current value of $20 billion, which clearly shows the industries trending business opportunities. Thus, this summit is one of the most important opportunities, where you will explore your business potential in this trending industry. It is particularly important for the fields key opinion leaders, most exciting new-comers and others to come together to discuss and learn about the up-to-the-minute trends of biosimilars, commercial strategy, effective planning and strategies for biosimilars future development, etc. It will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in the biosimilars industry. The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities.

KEY TOPICS

EU, US and international regulatory aspects

The use of innovative bio-analytics

Risk management Stratgies for biosimilars

From biosimilars to biogenerics

Numeracy and the Understanding of Clinical Trials with Biosimilars

Biosimilars regulatory affairs

Emerging investment trends and opportunities

Combination products and self-injection devices for biosimilars: Opportunities and pitfalls

Opportunities and pitfall in medical communication for biosimilar products

What can we learn from real life data?

Challenges of Biosimilar Labeling

Establishing “Finger-print Like” Biosimilarity – Critical Characterization Steps for Biosimilar Assessment

Biosimilar insulin, regulatory profile and challenges for gaining marketing authorization approval

Are you on track? – Rapidly evolving regulatory landscape for the development of Biosimilars

The Future of Biosimilars Testing and Development

WHY YOU SHOULD BE HERE?

Network with business development and licensing professionals as well as professionals in your sector

Implement the latest innovations

Learn about the latest technologies and most pressing topics specific to your business

Get an overview on innovative emerging technologies and promote business partnerships within the sector

Interact and connect with leading professionals

Discuss about new opportunities for your products and services with key decision makers

FEATURED SPEAKERS

Cecil Nick

Vice President

PAREXEL International

Fiona M Greer BSc (Hons) MSc PhD

Agriculture, Food and Life Global Director, BioPharma Services Development – Life Sciences

SGS

Dr. Jakob Lange, Ph.D.

Account Director

Ypsomed AG

Dr. Steinar Madsen

Medical Director

Norwegian Medicines Agency

Uwe Gudat

Head of Safety, Biosimilars

Merck

Fredrik Sundberg

Global Director, Strategic Market Development

GE Healthcare

Grzegorz Orlik, MD

Head of Medical Affairs, Biosimilars and Generics (Europe)

Accord Healthcare

Christian Maasch

Managing Consultant Product Development and RA

Xendo Deutschland GmbH

Chantal LE FLOCH

Head of GRA-EU-DCV

Sanofi

FEATURED COMPANIES

SPONSOR

MEDIA PARTNERS

REQUEST FORM

YOUR FULL NAME *

COMPANY NAME *

TELEPHONE

CORPORATE EMAIL *

HOW CAN WE HELP YOU?

PICK THE EVENT YOU'RE INTERESTED IN

MESSAGE

Click here to indicate that you have read and agree to our privacy policy.

28
Feb

GLOBAL CDx & PERSONALIZED MEDICINE SUMMIT

Categories:

GLOBAL CDx & PERSONALIZED MEDICINE SUMMIT

Sharonat International is pleased to invite you to the “Global CDx & Personalized Medicine Summit” scheduled on March 8 – 9, 2018 in Berlin, Germany.

KEY TOPICS

WHY YOU SHOULD BE THERE ?

Novel Diagnostic Technologies
Strategic Partnerships for CDx – Challenges and Opportunities
Partnering strategies to achieve successful commercialization of CDx
Implementation of a Personalized Medicine program
Emerging approach to precision medicine strategy
Partnering to Deliver Personalized Medicine
Finding the appropriate business models for CDx companies
The role of complementary diagnostics in targeted therapy selection
The laboratory developed test (LDT) & In vitro diagnostic (IVD) Models
Liquid biopsy methodologies for non-invasive diagnostic development
Next generation sequencing protocols
Regulatory Update on Companion Diagnostics

1. Meet with experts and influencers in your industry face to face.

2. Learn about the latest technologies and most pressing topics specific to your business.

3. Discuss about new opportunities for your products and services with key decision makers.

4. Get new tips, tactics and implement the latest innovations.

5. Get an overview on innovative emerging technologies and business partnership opportunities.

6. Interact and connect with leading companies and their representatives.

FEATURED SPEAKERS

Edward Abrahams, Ph.D.

President

Personalized Medicine Coalition

Dr. Reinhard Ortmann

Director Partnering for Precision Diagnostics

QIAGEN

Paul Docherty

Relationship and Alliance Manager

Hologic Ltd.

Dr. Annette O. Walter

Director, Oncology Biomarker Strategist

Bayer

Susanne Munksted

Global Commercial Director, Companion Diagnostics

Agilent Technologies

Robert Hewitt, MB BS, PhD

Director Biobank Consortia and Communications

Trans-Hit Biomarkers Inc.

FEATURED COMPANIES

MEDIA PARTNERS

REQUEST FORM

YOUR FULL NAME *

COMPANY NAME *

TELEPHONE

CORPORATE EMAIL *

HOW CAN WE HELP YOU?

PICK THE EVENT YOU'RE INTERESTED IN

MESSAGE

Click here to indicate that you have read and agree to our privacy policy.

27
Feb

WORLD BIOBANKING SUMMIT

Categories:

WORLD BIOBANKING SUMMIT

The global biobanking market was USD 142 million in 2011 and it is forecasted that this market will reach USD 216.3 million in 2018 with the compound annual growth rate of 5.4 % from 2011 – 2018. Moreover, the biobanking market witnessed an increased trend of mergers and acquisitions among vendors. This summit will address the latest developments in biobanking from its discovery to commercialization. It is one of the most important opportunities, where you will explore your business potential in biobanking. The U.S and Europe have the largest market size in biobanks. However, the rapid growth in population in Asia Pacific countries will affect the market of the developed countries. This summit will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in biobanking. The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities.

KEY TOPICS

Quality management system in biobanking

Latest technological developments in biobanking

Strategic Partnerships for Biobanking – Challenges and Opportunities

Biobanking In Emerging Markets – Regulatory and Commercial Considerations

Biostatistics and data management

Cloud-Based Sample Management

Biobanking discovery to commercialization

Automated biobanking

Biobanks in clinical and translational research

WHY YOU SHOULD BE HERE?

Network with business development and licensing professionals as well as professionals in your sector

Implement the latest innovations

Learn about the latest technologies and most pressing topics specific to your business

Meet with experts and influencers in your industry face to face

Get an overview on innovative emerging technologies and explore your business potential

Interact and connect with leading companies and their representatives

Discuss about new opportunities for your products and services with key decision makers

Get new tips, tactics and implement the latest innovations

FEATURED SPEAKERS

Mag. Dr. Helmuth Haslacher, BSc BA

Biobank-Coordinator, QM-Coordinator

MedUni Wien Biobank

Peadar Mac Gabhann

Managing Director

Biostór Ireland

Dr. Balwir Matharoo-Ball

President of ESBB & Deputy Director

Nottingham Health Science Biobank

Dr. Rita T. Lawlor, PhD

Biobank Director

ARC-Net Center for Applied Research on Cancer

Paul Lomax

Product Manager

TTP Labtech

Robert Hewitt, MB BS, PhD

Director Biobank Consortia and Communications

Trans-Hit Biomarkers Inc.

Dr. Dejun Tang

Global Head of Biostatistics & Clinical Submission Management

Sandoz, a Novartis Division

Prof. Jens K. Habermann, M.D., Ph.D.

President of ESBB & Director

Interdisciplinary Center for Biobanking-Lübeck

Isabel Gil Aldea, MD, PhD

Biobank Scientific Director

NAVARRABIOMED

Mark Divers, PhD

Executive Director

Karolinska Institutet Biobank

Audrey Schenker

LIMS Application Engineer, Biobank Specialist

Genohm SA, a part of Agilent Technologies Inc.

FEATURED COMPANIES

MEDIA PARTNERS

Dr. Robert Hewitt, Chair Person, World Biobanking Summit

YOUR FULL NAME *

COMPANY NAME *

TELEPHONE

CORPORATE EMAIL *

HOW CAN WE HELP YOU?

PICK THE EVENT YOU'RE INTERESTED IN

MESSAGE

Click here to indicate that you have read and agree to our privacy policy.